crenolanib

01/01/2017 - "In conclusion, our study highlights PDGFRB as target with a clear role in MPM tumorigenesis and provided a rationale to explore further the efficacy of crenolanib in MPM patients, with promising results."

01/01/2019 - "Crenolanib (CP-868,596), a potent inhibitor of FLT3 and PDGFRα/β, is currently under phase III clinical investigation for the treatment of acute myeloid leukemia. "
01/01/2019 - "Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms."
01/02/2014 - "Finally, correlative data from an ongoing clinical trial demonstrate that acute myeloid leukemia patients can achieve sufficient levels of crenolanib to inhibit both FLT3/ITD and resistance-conferring FLT3/D835 mutants in vivo. "
11/21/2013 - "Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia."
01/01/2022 - "To evaluate the safety, activity, and emergence of FLT3-kinase domain (KD) mutations with combination therapy of crenolanib and sorafenib in acute myeloid leukemia (AML) with FLT3-internal tandem duplication (ITD). "

01/01/2017 - "Treatment with crenolanib attenuated the skin and heart fibrosis. "
12/01/2016 - "In DMD, treatment of mdx mice with crenolanib, a highly selective PDGFRα/β tyrosine kinase inhibitor, reduced fibrosis, improved muscle strength, and was associated with decreased activity of Src, a downstream effector of PDGFRα signalling. "
01/01/2017 - "Our aim was to examine the therapeutic potential of crenolanib, an inhibitor of PDGF receptor signaling, in cultured fibroblasts and in angiotensin II-induced skin and heart fibrosis. "

01/01/2021 - "After TAA treatment, the animals received Crenolanib for two weeks, which significantly improved recovery from liver fibrosis. "
01/01/2021 - "In conclusion, the Crenolanib-mediated inhibition of RTK impeded HSC proliferation and triggered stress responses, initiating developmental processes in HSC that might have contributed to improved recovery from liver fibrosis in TAA-treated rats."
01/01/2021 - "Improved Recovery from Liver Fibrosis by Crenolanib."

01/01/2022 - "To understand how clonal evolution contributes to the tumor's invasive spread, we performed exome sequencing and SNP array profiling on 49 multi-region autopsy samples from 11 patients with pontine DMG-H3 K27-a enrolled in a phase I clinical trial of PDGFR inhibitor crenolanib. "
01/01/2021 - "Importantly, the PDGFR-specific inhibitor crenolanib significantly reduced intracranial growth of mammary tumor cells. "
01/01/2014 - "Injection of crenolanib significantly inhibited the growth of tumor mass by inducing apoptosis in tumor cells. "
01/01/2014 - "Furthermore, the in vivo antitumor activity of crenolanib was confirmed in an NSCLC xenograft tumor model. "
08/15/2012 - "To determine the potential of crenolanib, a potent inhibitor of PDGFRA, to treat malignancies driven by mutant PDGFRA. "